3 836

Cited 0 times in

Folfox4 as a Rescue Chemotherapy for Gemcitabine-Refractory Pancreatic Cancer

DC Field Value Language
dc.contributor.author박승우-
dc.contributor.author박정엽-
dc.contributor.author방승민-
dc.contributor.author송시영-
dc.contributor.author장희원-
dc.contributor.author정문재-
dc.contributor.author정재복-
dc.contributor.author정주원-
dc.date.accessioned2014-12-18T09:20:04Z-
dc.date.available2014-12-18T09:20:04Z-
dc.date.issued2013-
dc.identifier.issn0172-6390-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/87977-
dc.description.abstractBACKGROUND/AIMS: This phase II study assessed the efficacy and safety of FOLFOX4 as a rescue therapy in patients with gemcitabine-refractory pancreatic cancer. METHODOLOGY: The study included patients with advanced pancreatic cancer who had failed gemcitabine-based chemotherapy. FOLFOX4 was administered biweekly as follows: oxaliplatin, 85 mg/m² as a 2-hour infusion (day 1); leucovorin, 200 mg/m²/day as a 2-hour infusion (days 1 and 2); 5-fluorouracil, bolus 400 mg/m²/day and 600 mg/m²/day as a 22-hour infusion (days 1 and 2). RESULTS: Forty-four patients received a total of 264 cycles of chemotherapy. There was 1 complete response (2.2%), 4 partial responses (9.1%), and 13 stable diseases (29.5%). The objective response rate was 11.4% and the tumor stabilization rate was 40.9%. The median time to progression was 9.9 weeks (95%CI: 8.2-11.5) and the median overall survival was 31.1 weeks (95%CI: 24.4-37.9). The common adverse events were hematologic toxicities: grade 3 or 4 neutropenia in 19 patients (43.2%), anemia in 9 patients (20.5%), and thrombocytopenia in 6 patients (13.5%). Grade 3 or 4 neuropathy occurred in 4 patients (9.1%). CONCLUSIONS: In gemcitabine-refractory pancreatic cancer, FOLFOX4 showed encouraging activity and was generally well-tolerated. However, careful attention needs to be paid to hematologic toxicities.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfHEPATO-GASTROENTEROLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHDeoxycytidine/adverse effects-
dc.subject.MESHDeoxycytidine/analogs & derivatives*-
dc.subject.MESHDeoxycytidine/therapeutic use-
dc.subject.MESHFemale-
dc.subject.MESHFluorouracil/adverse effects-
dc.subject.MESHFluorouracil/therapeutic use-
dc.subject.MESHHumans-
dc.subject.MESHLeucovorin/adverse effects-
dc.subject.MESHLeucovorin/therapeutic use-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOrganoplatinum Compounds/adverse effects-
dc.subject.MESHOrganoplatinum Compounds/therapeutic use-
dc.subject.MESHPancreatic Neoplasms/drug therapy*-
dc.subject.MESHPancreatic Neoplasms/mortality-
dc.subject.MESHPrognosis-
dc.titleFolfox4 as a Rescue Chemotherapy for Gemcitabine-Refractory Pancreatic Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorChung JW-
dc.contributor.googleauthorJang HW-
dc.contributor.googleauthorChung MJ-
dc.contributor.googleauthorPark JY-
dc.contributor.googleauthorPark SW-
dc.contributor.googleauthorChung JB-
dc.contributor.googleauthorSong SY-
dc.contributor.googleauthorBang SM-
dc.identifier.doi23858557-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01551-
dc.contributor.localIdA01647-
dc.contributor.localIdA01786-
dc.contributor.localIdA02035-
dc.contributor.localIdA03499-
dc.contributor.localIdA03602-
dc.contributor.localIdA03706-
dc.contributor.localIdA03726-
dc.relation.journalcodeJ00984-
dc.identifier.pmid23858557-
dc.subject.keywordAdult-
dc.subject.keywordAged-
dc.subject.keywordAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.keywordAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.keywordDeoxycytidine/adverse effects-
dc.subject.keywordDeoxycytidine/analogs & derivatives*-
dc.subject.keywordDeoxycytidine/therapeutic use-
dc.subject.keywordFemale-
dc.subject.keywordFluorouracil/adverse effects-
dc.subject.keywordFluorouracil/therapeutic use-
dc.subject.keywordHumans-
dc.subject.keywordLeucovorin/adverse effects-
dc.subject.keywordLeucovorin/therapeutic use-
dc.subject.keywordMale-
dc.subject.keywordMiddle Aged-
dc.subject.keywordOrganoplatinum Compounds/adverse effects-
dc.subject.keywordOrganoplatinum Compounds/therapeutic use-
dc.subject.keywordPancreatic Neoplasms/drug therapy*-
dc.subject.keywordPancreatic Neoplasms/mortality-
dc.subject.keywordPrognosis-
dc.contributor.alternativeNamePark, Seung Woo-
dc.contributor.alternativeNamePark, Jeong Youp-
dc.contributor.alternativeNameBang, Seung Min-
dc.contributor.alternativeNameSong, Si Young-
dc.contributor.alternativeNameJang, Hui Won-
dc.contributor.alternativeNameChung, Moon Jae-
dc.contributor.alternativeNameChung, Jae Bock-
dc.contributor.alternativeNameChung, Joo Won-
dc.contributor.affiliatedAuthorPark, Seung Woo-
dc.contributor.affiliatedAuthorPark, Jeong Youp-
dc.contributor.affiliatedAuthorBang, Seung Min-
dc.contributor.affiliatedAuthorSong, Si Young-
dc.contributor.affiliatedAuthorJang, Hui Won-
dc.contributor.affiliatedAuthorChung, Moon Jae-
dc.contributor.affiliatedAuthorChung, Jae Bock-
dc.contributor.affiliatedAuthorChung, Joo Won-
dc.rights.accessRightsnot free-
dc.citation.volume60-
dc.citation.number122-
dc.citation.startPage363-
dc.citation.endPage367-
dc.identifier.bibliographicCitationHEPATO-GASTROENTEROLOGY, Vol.60(122) : 363-367, 2013-
dc.identifier.rimsid32678-
dc.type.rimsART-
Appears in Collections:
6. Others (기타) > Dept. of Health Promotion (건강의학과) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.